1.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
2.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000706370, COG-AALL1131, AALL1131, NCT01406756
3.	A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects = 60 Years Old With Newly Diagnosed ALL Phase: Phase III Type: Treatment Status: Active Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TTX404, NCT01439347
4.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Phase: Phase III Type: Behavioral study, Treatment Status: Active Age: 1 to under 31 Sponsor: NCI Protocol IDs: NCI-2009-00307, AALL0434, CDR0000514500, COG-AALL0434, U01CA98543, NCT00408005
5.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
6.	Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: 2010-0991, NCT01371630
7.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
8.	Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: CHSC835X2201, NCT01474681
9.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
10.	CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2012-0265, NCT01664910
11.	Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201303012, NCT01747499
12.	Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
13.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
14.	Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2006-0328, NCT00501826
15.	Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 08-087, NCT00739141
16.	Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 to 60 Sponsor: NCI Protocol IDs: NCI-2009-00800, S0805, CDR0000624250, U10CA032102, SWOG-S0805, NCT00792948
17.	Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 12 to 40 Sponsor: Other Protocol IDs: 2006-0375, NCT00866749
18.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
19.	CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase: Phase II Type: Treatment Status: Active Age: 0 to 26 Sponsor: Other Protocol IDs: L 10,321, NYMC 525, NCT01049854
20.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485
21.	Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and over Sponsor: NCI Protocol IDs: NCI-2011-02621, CALGB 10701, CDR0000690286, CALGB 10701/CTSU C10701, U10CA031946, NCT01256398
22.	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2206.00, NCI-2010-02222, P01CA018029, NCT01251575
23.	Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0598, NCT01319981
24.	Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: UCBT01, NCT01328496
25.	Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0708, NCT01363128